FDA extends review of Capricor cell therapy; Pain drug startup to go public
The agency is now reviewing an updated application for deramiocel with a “refined” indication. Elsewhere, a startup co-founded by Vivek Ramaswamy is taking a speedy path to the public markets.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.